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Abstract
Phorbol esters, which are protein kinase C (PKC) activators, and histone deacetylase
(HDAC) inhibitors, which cause enhanced acetylation of cellular proteins, are the main clas-
ses of chemical inducers of Epstein-Barr virus (EBV) lytic cycle in latently EBV-infected
cells acting through the PKC pathway. Chemical inducers which induce EBV lytic cycle
through alternative cellular pathways may aid in defining the mechanisms leading to lytic
cycle reactivation and improve cells’ responsiveness towards lytic induction. We performed
a phenotypic screening on a chemical library of 50,240 novel small organic compounds to
identify novel class(es) of strong inducer(s) of EBV lytic cycle in gastric carcinoma (GC) and
nasopharyngeal carcinoma (NPC) cells. Five hit compounds were selected after three suc-
cessive rounds of increasingly stringent screening. All five compounds are structurally
diverse from each other and distinct from phorbol esters or HDAC inhibitors. They neither
cause hyperacetylation of histone proteins nor significant PKC activation at their working
concentrations, suggesting that their biological mode of action are distinct from that of the
known chemical inducers. Two of the five compounds with rapid lytic-inducing action were
further studied for their mechanisms of induction of EBV lytic cycle. Unlike HDAC inhibitors,
lytic induction by both compounds was not inhibited by rottlerin, a specific inhibitor of PKCδ.
Interestingly, both compounds could cooperate with HDAC inhibitors to enhance EBV lytic
cycle induction in EBV-positive epithelial cancer cells, paving way for the development of
strategies to increase cells’ responsiveness towards lytic reactivation. One of the two com-
pounds bears structural resemblance to iron chelators and the other strongly activates the
MAPK pathways. These structurally diverse novel organic compounds may represent
potential new classes of chemicals that can be used to investigate any alternative mecha-
nism(s) leading to EBV lytic cycle reactivation from latency.
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Introduction
Epstein-Barr virus (EBV) is a ubiquitous gammaherpesvirus which infects over 90% of the
adult population worldwide. Its acute infection sometimes causes infectious mononucleosis,
though most of the time its infection is asymptomatic [1, 2]. EBV adopts a biphasic life cycle as
other herpesviruses and persists in latencies in infected cells after initial infection, expressing
only a limited number of viral proteins and transcripts. Reactivation of the latent virus into
lytic cycle induces the expression of a temporally regulated cascade of approximately 80 lytic
proteins. The reactivation of lytic cycle in latently-infected cells can be induced by a variety of
agents, e.g. anti-immunoglobulin [3, 4], tumour growth factor β (TGF-β) [5, 6], and different
groups of chemicals [7]. Histone deacetylase (HDAC) inhibitors [8–11] and phorbol esters
[12–14] are the major classes of chemical lytic inducers reported thus far.
EBV has been suggested to underlie the development of various lymphoid and epithelial
cancers for their persistence in the infected cells, e.g. Burkitt lymphomas (BL), Hodgkin lym-
phomas, nasopharyngeal carcinoma (NPC), gastric carcinoma (GC), etc. Although EBV is
present in latent states in these tumours, substantiating the importance of latent infection in
oncogenesis, accumulating evidence has also pointed to the possible contribution of EBV lytic
reactivation towards tumour development. Fang et al. [15, 16] reported that repeated lytic reac-
tivation by chemical lytic inducers enhanced genome instability in NPC cells and promoted
tumour progression in NPC mouse xenograft models. Hong et al. showed that for lymphoblas-
toid cell lines (LCLs), those with immediately-early gene-deleted EBV genomes incapable of
going into lytic cycle produced lower level of the angiogenesis factor vascular endothelial
growth factor (VEGF) [17], and less capable of forming tumours in a SCID mice model [18].
Despite such implication in disease progression, the presence of EBV in these tumours presents
a unique target that can be exploited for treating EBV-positive malignancies. Lytic induction
therapy, in which a combination of lytic inducer and antiviral drug is employed for the specific
killing of EBV-positive tumour cells, is one of such strategies [9, 19–21]. Antiviral drugs for
herpesviruses, e.g. acyclovir and ganciclovir, are originally non-cytotoxic to these EBV-positive
tumours since the viruses in latent states do not express the viral protein kinase BGLF4
required to convert these drugs to an active cytotoxic form [22]. However, when the latent
viruses are induced into lytic cycle and express BGLF4, the drugs can be converted into the
cytotoxic form by the viral kinases and kill the cancer cells. This method has been demon-
strated to be effective in in vitro assays and mouse models [19, 23, 24], and has been entering
clinical trials [9, 20, 21]. One limiting factor of the effectiveness of this therapeutic strategy is
the cells’ responsiveness to EBV lytic induction. In vitro, the efficacy of these chemical lytic
inducers is highly dependent on cellular background [10, 25–28], and there remains a cell pop-
ulation refractory to lytic induction upon the application of any agents. Increasing the cells’
responsiveness is thus vital to the development of this novel therapeutic strategy.
To this end, a lot of efforts have been dedicated to studying the mechanisms EBV lytic reac-
tivation in vitro with EBV-positive B cells or epithelial cells as models. To date, a number of
kinase pathways, including the phosphatidylinositol 3-kinase (PI3K) [5], mitogen-activated
protein kinases (MAPKs) [29–32], protein kinase C (PKC) [8, 14, 33], and ataxia telangiectasia
mutated (ATM) kinase [7] pathways, have been reported to mediate lytic reactivation by lytic
inducing stimuli in different cell backgrounds. In particular, the chemical inducers phorbol
ester 12-O-tetradecanoylphorbol-13-acetate (TPA) and HDAC inhibitors have been reported
to act through PKC to activate the transcription of the immediately-early (IE) protein Zta [8,
14, 33, 34], whose expression alone is sufficient to trigger the switch from latent to lytic cycle
[35, 36]. Nevertheless, conflicting evidence suggests that activation of PKC is neither sufficient
nor necessary for lytic induction by HDAC inhibitors [28]. More thorough understanding of
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the molecular events leading to lytic reactivation is vital to devising strategies to achieve higher
responsiveness of any chemical intervention.
We conceive that the identification of novel organic molecules to induce EBV lytic cycle
would add to the pool of stimulants for the in vitro study of mechanisms leading to lytic reacti-
vation, we performed a high-throughput screening with more than 50,000 small novel organic
molecules, and identified 5 structurally diverse compounds that can potently induce EBV lytic
cycle in EBV-positive epithelial malignancies. Compared to HDAC inhibitors and phorbol
esters, these novel compounds are structurally distinct and do not seem to possess similar bio-
logical activities. They can also act in concert with HDAC inhibitors to synergistically induce
lytic cycle. Thus we consider them as attractive targets for further study into the mechanism of
action of lytic reactivation and as lead compounds to uncover new classes of chemical EBV
lytic inducers.
Materials and Methods
Cell Culture
AGS is an EBV-negative gastric carcinoma (GC) cell line [37], and AGS-BX1 was generated by
introducing an recombinant Akata EBV genome into AGS cells (gifts from Prof. Lindsey M.
Hutt-Fletcher, Louisiana State University, LA) [38]. HONE1-EBV was generated by introduc-
ing a recombinant Akata EBV genome into the EBV-negative NPC cell line HONE1 (gift from
Prof. GSW Tsao) [39]. These three cell lines were cultured as previously described unless other-
wise specified [10, 40]. Both AGS-BX1 and HONE1-EBV cells contain a green fluorescent pro-
tein (GFP) open reading frame in the EBV genome. NA is a Taiwanese EBV-positive NPC cell
line obtained by infecting the EBV-negative TW01 cell line with an Akata EBV genome carry-
ing neomycin-resistant gene (gift from Prof. Ching-Hwa Tsai and Prof. Jen-Yang Chen,
National Taiwan University, Taiwan). It was maintained in RPMI-1640 (Life Technologies)
supplemented with 10% heat-inactivated fetal bovine serum (FBS; Life Technologies) and
500μg/ml G418 (Merck KGaA, Damstadt, Germany) [41]. SNU-719 [42, 43] (Korean Cell Line
Bank, No. 00719) and YCCEL1 [44] (gift from Prof. Qian Tao, The Chinese University of
Hong Kong, Hong Kong) are EBV-positive GC cell lines harbouring native EBV genomes.
C666-1 is an EBV-positive NPC cell line harboring native EBV genomes [45]. Daudi is an
EBV-positive Burkitt lymphoma cell line that is permissive to EBV superinfection [10]. These
four cell lines were maintained in RPMI-1640 supplemented with 10% heat-inactivated FBS.
Chemicals
The small organic molecules for primary high-throughput screening, secondary screening, ter-
tiary screening and subsequent characterization were all obtained from ChemBridge Corp.
(San Diego, CA, USA). Suberoylanilide hydroxamic acid (SAHA) was obtained from Cayman
Chemical (Ann Arbor, MI, USA). Romidepsin and Ku-55933 (Ku) were obtained from Selleck
Chemicals (Houston, TX, USA). LY294002 (LY), PD98059 (PD), SP600125 (SP), SB202190
(SB) and rottlerin were purchased fromMerck (Merck KGaA, Damstadt, Germany).
Assay for Cell Proliferation
Cell proliferation was assayed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT). EBV-positive AGS-BX1 cells and EBV-negative AGS cells (2×104 cells/well) were
seeded in 96-well cell culture plates and incubated overnight at 37°C, 5% CO2. Cells were either
untreated or treated with various concentrations of the lytic-inducing compounds for 48h in
triplicates. 10μl of MTT solution at 5mg/ml (Life Technologies) was then added to each well
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containing 100μl cells and the cells were then incubated at 37°C, 5% CO2 for 4h. 100μl 10%
SDS (w/v)/0.1M HCl was added to each well to lyse the cells and dissolve the resulted formazan
crystals. Measurement of absorbance at 570nm was carried out after overnight incubation of
the plates at 37°C with iMark Microplate Absorbance Reader (Bio-Rad, Hercules, CA). The
results shown were obtained from 5 independent experiments and standard errors were shown
as error bars.
Western Blot Analysis
Cells were grown to 70% confluence before treating with chemicals. At specified treatment
time, cells were harvested and the cell pellet was washed with phosphate buffered saline (PBS,
Sigma-Aldrich) once. Proteins were extracted from the cells and separated by 10% acrylamide
gels as previously described [10]. EBV proteins were detected as previously described [10, 40].
Histone acetylation was detected with anti-acetylated-histone 3 (H3) rabbit polyclonal anti-
bodies (1:2000, Millipore). Activation of the kinase pathways was detected with anti-p-p38
MAPK, anti-p-JNK, anti-p-PKCδ (1:1000) and anti-p-ATM (1:500) rabbit polyclonal antibod-
ies (Cell Signaling Technology). Expression of human α-tubulin or β-actin was detected with
anti-α-tubulin (1:5000) or anti-β-actin (1:10000) antibodies (Sigma-Aldrich) as loading
controls.
Quantitative PCR Assay
AGS-BX1 or NA cells grown to 70% confluence were treated with lytic-inducing compounds at
doses nearest to inhibiting 50% cell proliferation for 48h. Cells were harvested and washed
once with PBS. DNA was extracted from the cells and quantitative PCR was performed as pre-
viously described [10]. The results were presented as the number of EBV genome copies per
cell for triplicate wells in 96-well plates for each treatment condition.
Immunocytochemistry
AGS-BX1 cells were seeded on cover slips coated with 0.1% gelatin in 24-well cell culture plates.
Cells grown to 70% confluence were treated with the lytic-inducing compounds for 3 days,
then fixed and stained with anti-Zta mouse monoclonal antibody [46] (gift from Prof. P. Far-
rell, Imperial College London, UK) as previously described [10]. The nuclei of cells were visual-
ised with 4’,6’-diamidino-2-phenylidole (DAPI, Roche).
Flow Cytometry Analysis for Percentage Cells Induced into Lytic Cycle
AGS-BX1 cells were allowed to grow to 70% confluence before treatment with the lytic cycle
inducing compounds for 3 days. One million cells were collected for each condition and
washed once with PBS, followed by fixation and permeabilisation by the FACS fixation solu-
tion and FACS permeabilizing solution (BD Biosciences) for 30min each. Cells going into lytic
cycle were then stained by the anti-Zta mouse monoclonal antibody [46] (1:50 in 5% normal
goat serum) overnight at 4°C followed by Alexa Fluor 647 F(ab’)2 fragment of goat anti-mouse
IgG (1:500; Life Technologies) at 37°C for 1h. The stained cells were then subject to analysis by
flow cytometry (LSRII, BD Biosciences) and the Zta-positive population were taken as the pop-
ulation of cells induced into lytic cycle.
EBV Infection Assay
AGS-BX1 cells at 70% confluence were treated with the lytic-inducing compounds for 5 days
or untreated. The culture supernatants were collected and centrifuged, then filtered with
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0.45μm syringe filters (Sartorius Stedim Biotech, Goettingen, Germany). The filtered superna-
tants were used to superinfect Daudi cells as previously described [10]. The Daudi cells were
analysed by flow cytometry (LSRII, BD Biosciences) for GFP expression to give an estimation
of the level of infectious virus particles released into the culture supernatants upon compound
treatment.
Primary High-Throughput Screening (HTS)
The primary HTS was performed in a previously described automated Beckman Coulter Core
System (Fullerton) integrated with a Kendro robotics CO2 incubator (Thermo Scientific) at the
Department of Microbiology, LKS Faculty of Medicine, The University of Hong Kong [47].
The primary screening library comprised 50,240 structurally diverse small organic molecules
dissolved in dimethyl sulfoxide (DMSO) from the DIVERSet screening library from Chem-
Bridge Corp. (San Diego, CA, USA). These compounds were dispensed at a final concentration
of 20μg/ml in 384-well microliter plates in triplicate, to which AGS-BX1 cells were added at
6000 cells per well in 25μl Ham’s F12 (Life Technologies) supplemented with 5% heat-inacti-
vated FBS (Life Technologies). Two columns of untreated cells as negative controls and 5μM
SAHA-treated cells as positive controls were included in each plate. After 3-day incubation at
37°C with 5% CO2, green fluorescent signal was read at 535nm and recorded in DTX 880 mul-
timode detector (Beckman Coulter). The compounds which induced an increase in green fluo-
rescence signal larger than 1.5 fold of the negative control were selected as hits of the primary
HTS.
Secondary Screening
The secondary screening, the cytoblot assay, was performed with two cell lines, AGS-BX1 and
NA. 30,000 cells of AGS-BX1 or 10,000 cells of NA were seeded per well in white opaque
96-well plates (Greiner Bio-One) overnight before the addition of selected compounds. The
selected compounds were assayed at two concentrations, 1μg/ml and 10μg/ml, in duplicates.
After 24h incubation with the compounds at 37°C with 5% CO2, the induction of EBV lytic
cycle was detected by probing for the expression of the EBV immediately-early (IE) protein Zta
in cells using enhanced chemiluminescence after fixing the cells on plate with 4% paraformal-
dehyde in PBS for 15min and blocking with 0.5% bovine serum albumin (BSA, Sigma-Aldrich),
0.1% Triton X-100 in PBS for 1h. The cells after fixation and blocking were incubated with
anti-Zta monoclonal antibody [46] at 1:600 overnight at 4°C, after which horseradish peroxi-
dase-conjugated goat anti-mouse IgG at 1:1000 dilution were bound for 1h at room tempera-
ture and the luminescence signal were measured by a standard plate reader after the addition
of chemiluminescence substrate (Pierce, Thermo Scientific). A column of untreated cells and
5μM SAHA-treated cells were included as the negative and positive controls respectively. The
luminescent signals were normalised to the negative controls on the same plate, and com-
pounds with readings from both of the duplicate wells passing the cutoff value were ranked
based on the normalised reading, regardless of the concentrations used. Top 40 hits in each cell
line comprise the list of candidate compounds for next round of selection.
Tertiary Screening
The cytotoxicity of each selected compound in AGS-BX1 and NA cells was assayed by the
MTT assay at 5μg/ml, 10 μg/ml, 20 μg/ml and 40 μg/ml in duplicate after 48h of treatment.
The concentrations inhibited/or closest to inhibiting 50% cell proliferation were taken as IC50
and used in subsequent assays in the tertiary screening.
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More functional assays were employed at this stage to confirm the EBV lytic-inducing abil-
ity of the selected compounds. To compare the strength of lytic induction by the selected hit
compounds, AGS-BX1 or NA cells grown to 70% confluence were treated with the selected
compounds at their IC50 determined at 48h and harvested to examine the expression of various
lytic proteins, the IE proteins Zta and Rta, and the early protein EA-D (BMRF1) by Western
blot analysis. 22 compounds with strong expression of IE and early EBV lytic proteins were
selected for further comparison, including an additional round of Western blotting and quanti-
tative PCR to examine the replication of viral genome inside cells at 48h post-treatment.
Results
Phenotype-Based High-Throughput Screening (HTS) Identified 5 Novel
Organic Molecules that Can Potently Induce EBV Lytic Cycle in
EBV-Positive Epithelial Cancer Cells
AGS-BX1, an EBV-positive GC cell line, contains a GFP open reading frame in the BXLF1
gene in its EBV genome [38] and expresses GFP upon lytic induction with the fluorescent sig-
nal strength in approximate correlation to the strength of lytic induction [10], providing a
quantifiable readout for HTS. To identify novel organic molecules that can effectively reactivate
EBV lytic cycle, we screened a library of 50,240 small organic molecules from the DIVERSet
screening library (ChemBridge Corp.) with AGS-BX1 cells on the HTS platform established at
the Department of Microbiology at the University of Hong Kong, using GFP as readout (refer
to Fig 1A for an outline of the screening process). The molecules in the library were assayed for
3 days at 20μg/ml and 873 compounds displaying fluorescent signal larger than 1.5 fold of the
untreated controls were selected. The secondary screen, the Cytoblot assay, utilized NA, a Tai-
wanese EBV-positive NPC cell line, in addition to AGS-BX1. In this round of screening, the
lytic induction strength was assayed by detecting the expression of immediately-early (IE) viral
protein Zta in cells by chemiluminescence after 24h incubation with the test compounds, and
this further reduced the number of hit molecules to 40 in each cell line with the strongest
expression of Zta. Among the identified molecules, there were 11 overlaps for the two cell lines.
To validate the lytic inducing ability of these selected molecules, functional assays were per-
formed with these molecules at the concentrations that inhibited approximately 50% cell pro-
liferation (IC50) at the tertiary screening stage in both AGS-BX1 and NA cells, the two cell lines
used in the secondary screen. The 40 hits in each cell line were first tested with Western blot-
ting for their ability to trigger the expression of multiple EBV lytic proteins, including the IE
proteins Zta and Rta, and the early protein EA-D (BMRF1) (Fig 1B and S1A Fig). 22 molecules
from each cell line that induced strong expression of these proteins were selected for further
comparison (Fig 1C and S1B Fig). The 22 molecules on each cell line were tested again with
Western blotting for lytic protein expression, as well as with quantitative PCR for viral genome
replication (Fig 1D and S1C Fig) The molecules which induced strong expression of IE and
early lytic proteins, as well as viral genome replication in both cell lines were selected as hits of
the screening. By these criteria, 5 molecules were chosen based on their potent ability to induce
lytic cycle on both AGS-BX1 and NA cells (Fig 1E).
The Newly Identified Compounds Induce Lytic Cycle in a Dose-
Dependent, Time-Dependent and Cell Line-Dependent Manner
For detailed characterization of these newly identified compounds, we tested their cytotoxicity
in EBV-positive and EBV-negative paired cell lines. We also tested the dose response, kinetics
response of the compounds, the percentage of cells being induced into lytic cycle, and the
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Fig 1. High-throughput screening of a chemical library of 50,240 organic compounds for EBV lytic induction in EBV-positive epithelial
malignancies. (a) Flow chart of the screening process. (b) Expression of EBV immediately-early (IE) lytic proteins, Zta, Rta, and early protein EA-D (BMRF1)
in AGS-BX1 cells 48h post-treatment by the top 40 compounds in tertiary screening. The concentrations used were the approximate half inhibitory
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ability to induce the production of infectious virus in AGS-BX1 cells upon treatment by each
compound. Of the 5 compounds identified, 4 (compounds coded E11, C7, C8 and A10) dis-
played significantly higher toxicity to the EBV-positive cell line AGS-BX1 than the EBV-nega-
tive counterpart AGS at the lytic-inducing concentrations, demonstrating EBV-specific killing
of these compounds (Fig 2). The 5 compounds could all induce dose-dependent expression of
EBV viral lytic proteins at micromolar concentrations on AGS-BX1 cells, with maximal induc-
tion observed at doses ranging from 2.5 to 20μM (Fig 3A). The lytic induction kinetics varied
between compounds, the fastest of which being the compounds coded E11 and C7, with the
expression of IE proteins Zta, Rta, and early EBV lytic protein BMRF1 peaking at 24h post-
treatment. Other compounds exhibited slower lytic induction kinetics, with the expression of
concentration (IC50) for cell proliferation. The 22 compounds with an asterisk (*) below their code were selected for further comparison of lytic protein
expression and viral genome replication upon addition to the cells. (c) & (d) Expression of EBV IE and early proteins and replication of viral genome 48h post-
treatment induced by the selected 22 compounds on AGS-BX1 cells in tertiary screening. (e) Structure of the 5 hit compounds identified in the HTS. The
compound codes used for AGS-BX1 cells (NA cells), as well as the compound IDs at the ChemBridge Corp. catalogue are given below each structure.
doi:10.1371/journal.pone.0145994.g001
Fig 2. Cytotoxicity of the hit compounds in AGS and AGS-BX1 cells assayed by MTT at 48h post-treatment. AGS or AGS-BX1 cells were incubated
with various concentrations of the hit compounds for 48h and the cytotoxicity was assayed by MTT as described in the Materials and Methods section.
Results are expressed as percentages of the cell proliferation of the untreated cells and data from 5 independent experiments are presented. Standard errors
are shown in error bars. One-way ANOVA and Bonferroni post-test were performed in GraphPad Prism 5 to compare the difference in cell proliferation
between the EBV-positive AGS-BX1 and EBV-negative AGS cells (* p<0.05, ** p<0.01, ***p<0.001).
doi:10.1371/journal.pone.0145994.g002
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Fig 3. EBV lytic induction of the 5 hit compounds in the EBV-positive GC cells. AGS-BX1 cells were treated with (a) various concentrations of the hit
compounds or (b) the hit compounds at the concentrations which maximally induced lytic cycle (optimal concentrations) at various time points. Expression of
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Zta, Rta, and BMRF1 peaking at 48-72h post-treatment (Fig 3B). Interestingly, further time
point experiments revealed that the expression of the master switch protein of lytic cycle, Zta,
was detected even 15min after the incubation of E11 and C7 with the AGS-BX1 cells (S2 Fig).
Such fast action and high potency make them attractive targets for investigation into their
mechanism of action. Although all 5 compounds could potently induce the expression of IE
and early EBV lytic proteins, not all induced the expression of late proteins. Among the 5, only
E11 consistently induced the expression of late proteins, e.g. VCA-p18 and/or gp350/220 in
AGS-BX1, HONE1-EBV and YCCEL1 cells (Fig 3B and S3 Fig). The expression of late proteins
correlated closely with the production of infectious viral particles in the EBV infection assay. In
particular, after a 5-day incubation with the compound triggered the most expression of late
proteins E11, the filtered culture supernatant from AGS-BX1 cells infected 40% of the Daudi
cells in the EBV infection assay (Fig 3F)–the most among the 5 hit compounds. Immunofluo-
rescent staining of AGS-BX1 cells after 3-day incubation with the compounds revealed that
most of the Zta proteins were localised within the nuclei of cells (Fig 3D), consistent with their
role as a transcription transactivator and replication-associated factor [3, 48, 49]. We quanti-
fied the percentage of cells expressing Zta by flow cytometry to obtain an estimation of cells
going into lytic cycle. On average the Zta-positive population approximately ranged from 20%
to 40%, with E11 inducing the expression of Zta in up to 65% of cells (Fig 3E).
We further tested these newly discovered compounds in other EBV-positive epithelial can-
cer lines (Fig 4), as the action of most common lytic inducers has been reported to be cell line-
dependent [10, 25]. All the five compounds could reactivate lytic cycle in HONE1-EBV cells,
which is an NPC cell line with recombinant EBV genome. Not all compounds could reactivate
lytic cycle in the cell lines with native EBV genomes. 4 out of the 5 compounds reactivated EBV
lytic cycle in C666-1 cells, the only currently available authentic NPC cell line with native EBV
genomes. However, compound E11, which induced lytic cycle strongly in AGS-BX1 cells,
could not reactivate lytic cycle in C666-1 cells. For GC cell lines harbouring native EBV
genome, only compounds C7 and E7 reactivated lytic cycle in SNU-719 cells, and only E11, C7
and A10 could reactivate lytic cycle in YCCEL1 cells. Although the other 4 compounds exhibit
cell line-dependent induction, compound C7 could induce EBV lytic cycle in all the EBV-posi-
tive epithelial cancer cell lines tested at micromolar concentrations.
The Newly Identified Inducers Are Structurally and Biologically Distinct
from Classical Lytic Inducers
We compared the structures of the 5 novel compounds (Fig 1E) with each other and with those
of the classical lytic inducers, the HDAC inhibitors and the phorbol ester TPA (Fig 5D). Except
for the common possession of a hydrazone bridge for C7 and C8, the other hit compounds all
possess distinct chemical structures. They are, too, structurally different from the HDAC inhib-
itors and phorbol esters. We also tried to compare the biological activities of the new inducers
to HDAC inhibitors and phorbol ester. HDAC inhibitors, upon administration to the cells,
caused rapid and sustained hyperacetylation of histone proteins [23]. As shown in Fig 5A, the
various EBV lytic proteins were analysed with Western blotting with cellular β-actin as a loading control. (c) AGS-BX1 cells were treated with the hit
compounds at their optimal concentrations for 72h. The expression of Zta was visualized by immunofluorescent staining (red; middle panel) and the nuclei
were visualized by DAPI (blue; top panel). (d) AGS-BX1 cells were treated with the hit compounds at their optimal concentrations for 72h. The percentage of
cells induced into lytic cycle, i.e. expressing the IE protein Zta, was quantified by flow cytometry. (e) Production of infectious virions in AGS-BX1 cells after
treatment with the hit compounds. AGS-Bx1 cells, which are capable of producing GFP-tagged EBV virions, were first treated by the hit compounds for 5
days. The supernatants containing the virions produced were then collected and incubated with Daudi cells, which are susceptible to superinfection of EBV.
Percentage of superinfected Daudi cells, which were GFP-positive, were shown on the graph. The grey area represented unstained Daudi cells incubated
with culture medium only.
doi:10.1371/journal.pone.0145994.g003
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newly identified compounds did not cause hyperacetylation of the histone 3 protein (Acetyl-
H3), which is a marker for global histone hyperacetylation, after 24h incubation with
AGS-BX1 cells as by SAHA. They did not lead to significant increase in protein kinase C δ
(PKCδ) phosphorylation. We further investigated the biological effects of 2 of the 5 com-
pounds, E11, which induced the largest proportion of AGS-BX1 cells into lytic cycle, and C7,
which could induce all the cell lines tested into lytic cycle, in greater detail. We incubated these
two compounds with AGS-BX1 cells for 1h, 2h, 4h, 8h, 12h and 24h respectively at the
Fig 4. EBV lytic induction of the 5 hit compounds in several EBV-positive epithelial cell lines. (a) HONE1-EBV cells, (b) C666-1 cells, (c) SNU-719
cells, and (d) YCCEL1 cells were treated with the hit compounds at various concentrations for the specified period. HONE1-EBV cells contain a recombinant
Akata genome while C666-1 cells, SNU-719 cells and YCCEL1 cells all contain native EBV genomes. The expression of viral IE protein Zta after treatment
was detected by western blotting. The compound coded C7 could induce EBV lytic cycle in all the cell lines tested.
doi:10.1371/journal.pone.0145994.g004
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respective concentrations that maximally induce lytic cycle, and probed for the changes in sev-
eral major kinase signalling pathways previously associated with EBV lytic cycle reactivation
(Fig 5B). We observed strong and sustained phosphorylation of c-Jun N-terminal kinase (JNK)
Fig 5. Difference in structures and biological activities between hit compounds and classical lytic inducers. (a) AGS-BX1 cells were treated with the
hit compounds for 24h. Hyperacetylation of histone proteins and PKCδ phosphorylation were detected byWestern blotting. No significant increase in the
level of acetylated histone 3 (Acetyl-H3) and phosphorylated PKCδ was observed. (b) AGS-BX1 cells were treated by compound E11 or C7 for 1, 2, 4, 8, 12
24h. Changes in the phosphorylation of JNK and p38 MAPK were examined in conjunction with changes in the expression level of EBV proteins. JNK
phosphorylation increased and sustained during the treatment period while level of phosphorylated p38 MAPK fluctuated across the treatment period. (c)
AGS-BX1 cells were pre-treated with specific inhibitors of PI3K (LY294002, 15 μM, LY), MEK (PD98059, 50μM, PD), JNK (SP600125, 50μM, SP), p38
MAPK (SB202190, 20μM, SB), PKCδ (Rottlerin, 10μM) and ATM (KU-55933, 10μM, Ku) kinases for 1h before the addition of E11 and C7. Cells were harvest
after 24h for examination of lytic induction byWestern blotting. Lytic induction by E11 was significantly inhibited by SP, the specific JNK inhibitor while both
PD (MEK inhibitor) and SP affected the induction by C7. (d) Structure of common HDAC inhibitors, SAHA and romidepsin, and the phorbol ester TPA, used
for lytic induction of EBV. The structure of the newly identified compounds differs greatly from the known lytic inducers.
doi:10.1371/journal.pone.0145994.g005
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after treatment with E11 from 1h to 24h post-treatment, which was concurrent with the
increase in protein level of Zta. After we treated the cells with C7, there was also an increase in
phosphorylation of JNK at a level lower than that caused by E11 throughout the same treat-
ment period. However, romidepsin, an HDAC inhibitor, did not increase the phosphorylation
of JNK after 24h of treatment (S4 Fig). Apart from sustained increase in JNK phosphorylation,
we also observed fluctuations in the level of phosphorylation of p38 MAPK kinase. Upon treat-
ment of both compounds at 1h post-treatment, the level of p38 MAPK phosphorylation
increased. It then went down at 2h post-treatment and remained low afterwards for E11, while
the level went down from 2h to 12h then increased again at 24h post-treatment for C7. To test
if the activation of these kinase pathways mediated EBV lytic reactivation, we tried to block
these pathways with specific chemical pathway blockers of PI3K, MAPK/Erk kinase (MEK),
JNK, p38 MAPK, PKCδ and ATM, which have been previously associated with EBV lytic reac-
tivation [5, 8, 14, 29–33] (Fig 5C). We observed that only SP600125, a specific chemical inhibi-
tor of JNK, weakened the expression of Zta, Rta, and EA-D (BMRF1) significantly upon the
treatment by compound E11. For compound C7, more than one inhibitor appeared to be able
to counteract the induction, though the effect being more partial. PD98095, the specific inhibi-
tor of MEK, consistently reduced the expression of Rta, and SP600125 constantly reduced the
expression of Zta and EA-D (BMRF1), suggesting that the induction of C7 might not be mainly
mediated through a single pathway but two or more pathways. We have separately shown that
only rottlerin, the specific inhibitor of PKCδ, was able to abrogate the lytic induction by the
HDAC inhibitors romidepsin [23] and SAHA (S5 Fig). In comparison, compounds E11 and
C7 produced substantially different response patterns upon the co-incubation with these spe-
cific inhibitors, further substantiating their difference in mechanism of action with the typical
lytic inducers like HDAC inhibitors.
The Novel Inducers Cooperated with HDAC Inhibitors to Induce EBV
Lytic Cycle
The combination of two EBV lytic inducers does not necessarily reactivate EBV lytic cycle to a
greater magnitude. We have previously reported that combining bortezomib and SAHA, both
being reported to induce EBV lytic cycle on their own [10, 40, 50–52], decreased the magnitude
of lytic cycle induction while causing enhanced cell death in EBV-positive NPC cells [53]. We
are thus curious to know if these novel inducers could cooperate with the known inducers to
induce lytic cycle. We tested various combinations of concentrations of E11 and C7 with the
HDAC inhibitor romidepsin and SAHA in AGS-BX1 cells, and found that both HDAC inhibi-
tors could cooperate with E11 and C7 to induce EBV lytic cycle (Fig 6 and S6 Fig). For example,
Fig 6. Enhanced induction of EBV lytic cycle by the combination of hit compounds and the HDAC inhibitor romidepsin. AGS-BX1 cells were treated
with 2.5nM romidepsin (R) and various concentrations of E11 or C7 for 24h. Expression of viral IE protein Zta was detected byWestern blotting to estimate
the magnitude of lytic induction. The combinations with an asterisk (*) are the concentrations at which enhanced induction was observed.
doi:10.1371/journal.pone.0145994.g006
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2.5nM romidepsin, together with low doses (from 2.5 to 10μM of E11 or 1.25 to 2.5μM of C7)
of E11 and C7, synergistically induced the expression of the viral IE protein Zta (Fig 6). Simi-
larly, 2.5μM of SAHA could also synergise with 2.5 to 10μM of E11 or 1.25 and 2.5μM of C7 to
induce the expression of Zta (S6 Fig).
Discussion
Although EBV lytic reactivation has been implied in the pathogenesis of EBV-associated malig-
nancies such as NPC and EBV-associated lymphoproliferative diseases [15–18], it is also part
of the novel targeted therapeutic strategy–lytic induction therapy–which wakes up the dormant
EBV in associated cancer cells to render them susceptible to antiviral treatment [19, 23, 24].
Yet currently the in vivomechanism leading to of EBV reactivation remains largely elusive,
despite the demonstration of terminal differentiation of B cells [54] and differentiation of epi-
thelial cells being associated to induction of lytic cycle [46, 55]. The in vitromodels of reactiva-
tion have been better characterised with the help of chemical and physiological reagents that
serve as stimuli to trigger the start of the lytic cascade. Nevertheless, the major classes of chemi-
cal EBV lytic inducers reported thus far are mainly HDAC inhibitors and phorbol esters [10,
11, 13, 14]. The possibility of other chemical classes to induce lytic cycle in latently-infected
EBV cells has remained largely unexplored, with only one screening of a library of 2700 FDA-
approved drugs identifying the proteasome inhibitor bortezomib as a strong EBV lytic inducer
in B lymphoma cells [50, 51], and a recent study reported a new group of lytic inducers of the
tetrahydrocarboline class [56]. At the same time, by far most lytic inducers are cell line-depen-
dent [10, 25–28], which limited their potential to be developed into clinically useful agents.
Our study, thus, expands the pool of chemical EBV lytic inducers through our identification of
chemical compounds of diverse chemical structures.
The compounds for screening are from a chemical library of 50,240 drug-like molecules
with MW ranging from 300 to 700. Contrary to the previously reported HTS to screen for
novel lytic inducers [56], the 5 hit compounds we obtained in our screening were of diverse
structures, with the exception of compound C7 and C8, both with a hydrazone bridge, these
compounds do not seem to resemble each other in terms of structure, thus not possibly belong-
ing to the same chemical family. We argue this could represent the diversity of stimuli that can
trigger EBV reactivation in nature, and thus each of the identified hit compounds is a worth-
while target for further investigation. In addition, these hit compounds are structurally unre-
lated to the main classes of lytic inducers, the HDAC inhibitors and phorbol esters (Figs 1E
and 5D), suggesting they may possess different bioactivities from these classical EBV lytic
inducers. We thus further compared these compounds against HDAC inhibitors and phorbol
esters in terms of their biological action. Unlike HDAC inhibitors, these compounds do not
cause the hyperacetylation of histone proteins at various treatment concentrations, including
the lytic-inducing concentrations. We have also probed for the changes in phosphorylation of
PKCδ, the effector molecule that HDAC inhibitors and the phorbol ester TPA act through [8,
14, 23, 33], after the treatment by the hit compounds, yet no significant changes have been
observed (Fig 5A and 5B). We thus believe that, these compounds are neither HDAC inhibitors
nor PKC agonists. We have also attempted to compare our hits to the hits of the two other
reported screenings for EBV lytic inducers, the proteasome inhibitor bortezomib [50, 51] and
the tetrahydrocarbolines [56]. All of our five hits are structurally dissimilar to bortezomib and
the tetrahydrocarbolines. In terms of biological activities, although bortezomib has been found
to induce lytic cycle on EBV-positive B lymphoma cells [50–52], we found that its induction
was relatively weaker in EBV-positive epithelial cells, e.g. NPC cells [53]. In contrast, our hit
compounds induced lytic cycle strongly in EBV-positive epithelial cells, suggesting difference
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in the biological action between our hit compounds and bortezomib. Taken together, hits from
our screening are novel lytic inducers with distinct structures and mode of action from the clas-
sical lytic inducers that warrant further investigation.
In our detailed examination of lytic reactivation by these compounds, we found two com-
pounds that intrigued us. Compound E11 consistently reactivated EBV to full lytic cycle with
the expression of late viral proteins e.g. VCA-p18, gp350/220 in AGS, HONE1 background
cells with recombinant EBV genomes, as well as in YCCEL1 (S3 Fig), a Korean GC cell line
with native EBV genomes. It was able to induce the production of infectious viral particles in
AGS-BX1 and HONE1-EBV cells too. In addition, it reactivated a much higher percentage of
cells into lytic cycle compared with other compounds in AGS-BX1 cells, raising interest in its
mechanism of action. Besides compound E11, compound C7 is of special interest for its ability
to reactivate EBV lytic cycle in a diversity of EBV-positive epithelial cancer lines, including the
native EBV genome-carrying C666-1, SNU-719 and YCCEL1 cells. We thus investigated these
2 compounds in greater detail. These two compounds acted invariably fast in AGS-BX1 cells,
with the expression of viral IE protein, Zta, being detectable as early as 15min post-treatment
by both compounds (S2 Fig). Such fast kinetics also distinguish them from the HDAC inhibi-
tors e.g. romidepsin, in which the expression of Zta could only be observed after 12h of treat-
ment on cell lines of the same background [23], hinting the possibility of difference in mode of
action of the novel compounds compared to the HDAC inhibitors such as romidepsin. We
contemplate the fast action might be mediated through post-translational modification of sig-
naling molecules, and thus examined whether the incubation with E11 and C7 changes the
activation of signaling molecules in kinase pathways that have been previously reported to be
involved in lytic cycle reactivation. We found that concurrent with the induction of lytic cycle,
there was also a sustained activation of JNK and transient activation of p38 MAPK, suggesting
possible involvement of them in the induction of lytic cycle by these compounds. Experiments
using the specific pathway blockers to inhibit the relevant pathways indicated that only the
JNK inhibitor significantly abrogated the lytic reactivation by E11, and both the MEK inhibitor
and JNK inhibitor delivered partial inhibition towards lytic cycle induction by C7. We are
aware that caution has to be paid while interpreting data from the use of chemical inhibitors
and thus we reckon that further confirmation is required to confirm the role of JNK and/or
ERK pathways in leading to EBV lytic reactivation. Nevertheless, we have noted that rottlerin,
the PKCδ inhibitor that has been shown to abrogate lytic cycle induction by several HDAC
inhibitors, failed to significantly reduce lytic cycle induction E11 and C7, further supporting
the notion that these two compounds possess distinct mode of action from the HDAC inhibi-
tors. Although suppression of lytic induction could be observed for some inhibitors for the two
compounds, such suppression was only partial, indicating the possibility that more than one
pathway might be activated by each compound and those pathways act in concert to bring
about the activation of Zta and Rta transcription to start lytic cycle. We thus think that it
would be worthwhile to further investigate the mechanisms in which these new compounds
activate EBV lytic cycle, such that potential new pathways or new mode of action, could be
uncovered.
Combination of sodium butyrate, an HDAC inhibitor, and TPA, a PKC agonist, can syner-
gistically induce lytic cycle in a number of cells [10, 57]. This is used as a strategy to increase
the responsiveness of cells towards lytic induction. However, other combinations of lytic induc-
ing stimuli may not induce lytic cycle synergistically, instead, they counteract each other. For
example, combination of bortezomib, a proteasome inhibitor which could weakly induce lytic
cycle, and SAHA, an HDAC inhibitor, reduced the lytic induction strength although synergis-
tic killing of cancer cells could be achieved [53]. We thus tried to combine our newly identified
compounds with HDAC inhibitors extensively studied in our laboratory, romidepsin and
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SAHA. Interestingly, enhanced induction of lytic cycle was the most obvious at concentrations
where each of the agents did not induce lytic cycle strongly. Thus by combining the novel com-
pounds and an HDAC inhibitor, we could lower the concentration of either agent to 1/2 or
even 1/4 of the concentration when they were used as single agents to achieve the same or even
higher level of lytic induction. This offers an attractive potential to improve the responsiveness
of cells to lytic induction therapy, with the compounds serving as leads for further investigation
and development.
Owing to the ability of C7 to reactivate EBV lytic cycle in all the cell lines tested, we investi-
gated in greater detail if its structure displays similarity to any groups of known compounds or
drugs. The hydrazone bridge of C7 is a common structural entity among synthetic iron chela-
tors, e.g. 2-pyridylcarboxaldehyde isonicotinoyl hydrazone (PCIH) and its analogs [58], and
very similar to the well-known iron chelator di-2-pyridylketone-4,4-Dimethyl-3-thiosemicar-
bazone (Dp44mT) (Fig 7A and 7C). Among them, compound C7 bears the greatest resem-
blance to the 2-pyridylcarboxaldehyde m-bromobenzoyl hydrazone (PCBBH) (Fig 7B). It is
very likely that C7 also possess iron-binding or iron-chelating capabilities like PCBBH and
Dp44mT. As iron chelators have not been previously reported in research studies to induce
EBV lytic cycle in EBV-associated epithelial cancers, we reckon that further investigation into
this would open up a possibility to a new large class of chemicals that induce EBV lytic cycle in
EBV latently-infected cells.
In conclusion, our screening identified 5 novel organic compounds as EBV lytic inducers.
Their diverse chemical structures and different biological action from classical EBV lytic induc-
ers, e.g. HDAC inhibitors and TPA, make them attractive targets for further investigation. We
investigated 2 of the 5 compounds in greater detail, and found that both displayed fast lytic
Fig 7. Structures of iron chelators with structural similarity to C7. (a) The structure of the iron chelator
2-pyridylcarboxaldehyde isonicotyinoyl hydrazone (PCIH) and its analogues. (b) The structure of
2-pyridylcarboxaldehydem-bromobenzoyl hydrazone (PCBBH), the iron chelator in the PCIH series in which
C7 is most structurally similar to. (c) The structure of di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone
(Dp44mT), a well-known iron chelator.
doi:10.1371/journal.pone.0145994.g007
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inducting kinetics. One of them is a potent activator of the MAPK pathways, especially the
JNK pathway, while the other is structurally similar to iron chelators. While more efforts are
required to delineate the exact mechanism of action, these compounds represent good candi-
dates of new class(es) of EBV lytic inducing stimuli, new chemical tools to better decipher alter-
native mechanisms leading to activation of lytic cycle in latently-infected cells, and lead
compounds for further development to be used in conjunction with current lytic inducers to
improve responsiveness of cells to lytic induction.
Supporting Information
S1 Fig. Tertiary screening in NA cells. (a) Expression of EBV immediately-early (IE) lytic pro-
teins, Zta, Rta, and early protein EA-D (BMRF1) in NA cells 48h post-treatment by the top 40
compounds in tertiary screening. The concentrations used were the approximate half inhibi-
tory concentration (IC50) for cell proliferation. The 22 compounds with an asterisk () below
their code were selected for further comparison of lytic protein expression and viral genome
replication upon addition to the cells. (b) & (c) Expression of EBV IE and early proteins and
replication of viral genome 48h post-treatment induced by the selected 22 compounds on NA
cells.
(TIF)
S2 Fig. Lytic induction kinetics of the hit compounds at early periods of treatment.
AGS-BX1 cells were treated with the hit compounds at various time points to observe for the
time point in which increase in expression of the viral IE protein Zta was first detected. Com-
pound E11 and C7 is the fastest to induce lytic cycle, with the increase in Zta expression first
detected at 0.25h, i.e. 15min post-treatment.
(TIF)
S3 Fig. Expression of various lytic proteins induced by the hit compounds in HONE1-EBV
and YCCEL1 cells.HONE1-EBV cells or YCCEL1 cells were treated with the hit compounds
at their optimal concentration to induce lytic cycle. The expression of various EBV lytic pro-
teins was detected at different time points post-treatment. Compound E11 consistently
induced the expression of late proteins (e.g. p18-VCA) in cell lines it is capable of inducing
lytic cycle.
(TIF)
S4 Fig. Activation of the cellular kinase pathways by romidepsin and compound E11.
AGS-BX1 cells were treated with romidepsin (R) at 5nM for 24h or E11 at 20μM at the speci-
fied time points. Romidepsin treatment increased phosphorylation of PKCδ and ATM but not
JNK, while vice versa for E11.
(TIF)
S5 Fig. Rotterlin, a specific PKCδ inhibitor, inhibited lytic induction by the HDAC inhibi-
tor SAHA.HONE1-EBV cells were pre-treated with specific inhibitors of PI3K (LY294002,
15 μM), MEK (PD98059, 50μM), JNK (SP600125, 50μM), p38 MAPK (SB202190, 20μM) and
PKCδ (Rottlerin, 10μM) for 1h before the addition of 10μM SAHA. Cells were harvest after
48h for examination of lytic induction by western blotting. Only rottlerin significantly ham-
pered lytic induction by SAHA in HONE1-EBV cells.
(TIF)
S6 Fig. Enhanced induction of EBV lytic cycle by the hit compounds and the HDAC inhibi-
tor SAHA. AGS-BX1 cells were treated with 2.5μM of SAHA and various concentrations of
E11 or C7 for 24h. Expression of viral IE protein Zta was detected to by western blotting to
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estimate the magnitude of lytic induction. The combinations with an asterisk () are the con-
centrations at which enhanced induction was observed.
(TIF)
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